Literature DB >> 16764690

The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-alpha, IFN-gamma and iNOS mRNA.

Ute Kaim1, Andreas Moritz, Klaus Failing, Wolfgang Baumgärtner.   

Abstract

Canine cutaneous histiocytoma is a benign epidermal neoplasm of Langerhans cell origin, which usually displays spontaneous regression. Based on the degree of lymphocytic infiltration, 30 histiocytomas were classified into four groups representing different stages of tumour regression. To elucidate further the mechanisms of the antitumour immune response CD3+, CD21+, CD4+, CD8+ and myeloid/histiocyte antigen+ inflammatory cells were differentiated by immunohistochemistry and quantified. In addition, the number of apoptotic cells was detected using the TdT-mediated biotin-dUTP nick-end labelling (TUNEL) method. Furthermore, the expression of interleukin- (IL-2), IL-12(p40), tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), IL-10 and transforming growth factor-beta (TGF-beta) as well as inducible nitric oxid synthase (iNOS) mRNA was determined by reverse transcription-polymerase chain reaction (RT-PCR). Phenotyping of inflammatory cells revealed a significantly increased infiltration of all lymphocyte subsets and myeloid/histiocytic cells with the onset of tumour regression. The latter was significantly correlated to up-regulation of IL-2, TNF-alpha, IFN-gamma and iNOS mRNA expression. Expression of remaining cytokines and percentage of apoptotic cells showed no group-specific changes. The results indicate an initial infiltration of CD4+ T cells followed by increased expression of Th1 cytokines and recruitment of antitumour effector cells as the principal mechanism for tumour regression. Canine cutaneous histiocytoma is a unique example for an effective immune response in a naturally occurring neoplasm derived from epidermal Langerhans cells and might represent a valuable animal model to investigate tumour immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16764690      PMCID: PMC1782326          DOI: 10.1111/j.1365-2567.2006.02394.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

Review 1.  Interleukin-12 in anti-tumor immunity and immunotherapy.

Authors:  Mario P Colombo; Giorgio Trinchieri
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

Review 2.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

3.  Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2-integrin molecules.

Authors:  P F Moore; M D Schrenzel; V K Affolter; T Olivry; D Naydan
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

Review 4.  Tumor immunology--towards a paradigm of reciprocal research.

Authors:  Charles G Drake; Drew M Pardoll
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

Review 5.  Tumors derived from antigen presenting cells.

Authors:  H I Levitsky
Journal:  Semin Immunol       Date:  1996-10       Impact factor: 11.130

6.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

Authors:  S R Bennett; F R Carbone; F Karamalis; R A Flavell; J F Miller; W R Heath
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

7.  Expression of major histocompatibility complex class II antigen in neoplastic cells of canine cutaneous histiocytoma.

Authors:  A Kipar; W Baumgärtner; E Kremmer; K Frese; E Weiss
Journal:  Vet Immunol Immunopathol       Date:  1998-03-18       Impact factor: 2.046

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 9.  Modulation of the immune response by transforming growth factor beta.

Authors:  A Fontana; D B Constam; K Frei; U Malipiero; H W Pfister
Journal:  Int Arch Allergy Immunol       Date:  1992       Impact factor: 2.749

Review 10.  The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.

Authors:  L Bingle; N J Brown; Claire E Lewis
Journal:  J Pathol       Date:  2002-03       Impact factor: 7.996

View more
  4 in total

1.  A Role for Angiogenesis in Canine Cutaneous Histiocytoma Regression: Insights into an Old Clinical Enigma.

Authors:  Diana Costa; Rita Ferreira; Justina Prada; Felisbina Luisa Queiroga; Paula Rodrigues; Filipe Silva; Isabel Pires
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Morphology and immunophenotype of canine cutaneous histiocytic tumours with particular emphasis on diagnostic application.

Authors:  Katarzyna Paździor-Czapula; Tadeusz Rotkiewicz; Iwona Otrocka-Domagała; Michał Gesek; Anna Śmiech
Journal:  Vet Res Commun       Date:  2014-11-25       Impact factor: 2.459

3.  Characterization of MDCK cells and evaluation of their ability to respond to infectious and non-infectious stressors.

Authors:  Francesca Maria Capellini; Walter Vencia; Massimo Amadori; Giulia Mignone; Erica Parisi; Lucia Masiello; Barbara Vivaldi; Angelo Ferrari; Elisabetta Razzuoli
Journal:  Cytotechnology       Date:  2019-12-04       Impact factor: 2.058

4.  Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin.

Authors:  Juliana Vitoriano-Souza; Alexandre B Reis; Nádia D Moreira; Rodolfo C Giunchetti; Rodrigo Correa-Oliveira; Cláudia M Carneiro
Journal:  Vaccine       Date:  2008-05-22       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.